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Cross-presentation, in which exogenous antigens are presented via MHC I complexes, 
is involved both in the generation of anti-infectious and anti-tumoral cytotoxic CD8+ 
T cells and in the maintenance of immune tolerance. While cross-presentation was 
described almost four decades ago and while it is now established that some dendritic 
cell (DC) subsets are better than others in processing and cross-presenting internalized 
antigens, the involved molecular mechanisms remain only partially understood. Some 
of the least explored molecular mechanisms in cross-presentation concern the origin 
of cross-presenting MHC I molecules and the cellular compartments where antigenic 
peptide loading occurs. This review focuses on MHC I molecules and their intracellular 
trafficking. We discuss the source of cross-presenting MHC I in DCs as well as the role 
of the endocytic pathway in their recycling from the cell surface. Next, we describe 
the importance of the TAP peptide transporter for delivering peptides to MHC I during 
cross-presentation. Finally, we highlight the impact of innate immunity mechanisms on 
specific antigen cross-presentation mechanisms in which TLR activation modulates MHC 
I trafficking and TAP localization.
Keywords: MHC class i molecules, cross-presentation, endosomal recycling compartment, tubular endosomes, 
dendritic cells
A Short History of Major Histocompatibility Complex (MHC) 
identification
The MHC is a key component of the immune system that allows T lymphocytes to specifically detect 
foreign antigens in the context of a self-identification system. The discovery of MHC genes, as genetic 
loci controlling the immune response, originated from organ transplantation experiments and was 
performed between 1940 and 1970 by George D. Snell, Jean Dausset, and Baruj Bernacerraf, rewarded 
by the Nobel Prize in 1980 for these discoveries (1). In 1975, while studying the immune response of 
mice to viruses, Doherty and Zinkernagel demonstrated the relevance of T cell restriction by MHC. 
They showed that T cells were able to recognize viral peptides only if these peptides are bound to 
MHC and highlighted for the first time the phenomenon of “MHC restriction” (2). These major 
discoveries have also been rewarded, in 1996, by a Nobel Prize. The principle of parallel recognition 
of both self and non-self molecules was the basis for our current understanding of the specificity of 
July 2015 | Volume 6 | Article 3352
Adiko et al. MHC I trafficking and cross-presentation
Frontiers in Immunology | www.frontiersin.org
the cellular immune response. In parallel, the study of antibody 
response in inbred congenic animal models led to the discovery 
of MHC II and established the distinction between MHC I and 
MHC II [for a comprehensive review on MHC II discovery, see 
Ref. (3)].
Further research on MHC antigen presentation established that 
MHC I binds antigenic peptides derived from endogenous antigens 
and present them to CD8+ T cells, while MHC II binds antigenic 
peptides from exogenous antigens and present them to CD4+ T 
cells. This dichotomy is not absolute and exceptions exist at several 
levels. The most recent, and also one of the most surprising excep-
tions, is the discovery of an efficient CD8+ T cytotoxic response 
that is MHC II restricted, in the case of monkey vaccination with 
a cytomegalovirus vector expressing antigens from the simian 
immunodeficiency virus (4).
While the concept that CD8+ T cells are exclusively MHC I 
restricted has been re-evaluated only recently, the idea that MHC 
I present exclusively endogenous antigens has been reconsidered 
nearly 40 years ago, when Bevan discovered the phenomenon of 
CD8+ T cells cross-priming (5). He showed that minor histocom-
patibility antigens from transplanted cells can elicit a cytotoxic T 
cell response restricted by host MHC I molecules, which revealed 
that the source of antigenic peptides presented by MHC I might 
also be an exogenous antigen, and not only an antigen synthesized 
inside the presenting cell.
Contribution of Cross-Presentation to 
immunity and Self-Tolerance
The presentation of exogenous antigens by MHC I has been 
named cross-presentation. Following the discovery of CD8+ T 
cell cross-priming in transplant rejection (5), additional studies 
demonstrated that cross-presentation also occurs in the case of 
several cell-associated antigens, such as self-antigens (6), viral 
antigens (7), or antigens derived from tumoral cells (8). In addition 
to these typical cell-associated antigens, an important source of 
cross-presented material is the proteins synthesized by intracellular 
pathogens, such as Listeria (9), Plasmodium (10), or Leishmania 
(11). In these infections, the CD8+ T cells response contributes to 
protective immunity [reviewed in Ref. (12)].
Early during the study of cross-presentation, it was discovered 
that this process can lead not only to CD8+ T cell activation (T 
cell cross-priming) but also to T cell tolerance by either T cell 
anergy or T cell deletion [Cross-tolerance (13)]. How exactly 
cross-presentation influences the outcome of T cell response is 
a topic of particular interest that was extensively studied in the 
last two decade (14). Early after the discovery of tolerogenic 
abilities of cross-presentation, it has been supposed that there 
are several types of antigen cross-presenting cells, some which 
induce predominantly T cell activation and others that promote 
T cell tolerance. Alternatively, it has been proposed that the same 
antigen cross-presenting cell can be switched from a tolerogenic 
to an immunogenic status according to the nature of the engulfed 
antigenic material. As a result of significant efforts of several 
laboratories in the field, it became evident that in dendritic cells 
(DCs), it is the second scenario that reflects the plasticity of the 
cross-presentation process to orient the final outcome of the 
immune response toward cross-priming or cross-tolerance.
Overview of Dendritic Cell Populations
Dendritic cells are by far the most effective cross-presenting cells 
in both homeostatic and inflammatory conditions (15). As widely 
demonstrated by studies done both in humans and mice, DCs are 
a very heterogeneous cellular population (16–18). In a homeo-
static situation and without mentioning the skin and mucosal 
DCs, the murine DC system in lymphoid organs is composed 
of conventional DCs (CD8+ and CD8−) and plasmacytoïd DCs 
(pDCs). In humans, DCs found in the blood, spleen, and lymph 
nodes are classified as pDCs, BDCA1+ DCs, and BDCA3+ DCs. 
Based on gene-expression profiles, their function, and morphology, 
BDCA3+ DCs are considered to be the equivalent of murine CD8+ 
DCs and BDCA1+, the equivalent of murine CD8− DCs (19–22). 
Conventional DCs require for their differentiation the cytokine 
FMS-like tyrosine kinase 3 ligand (FLT3L) and additional sub-type 
specific transcription factors, describing differentiation pathways. 
A unified ontogeny-based nomenclature of mouse and human 
DCs has been recently proposed for conventional DCs, which are 
grouped in three main sub-types: classical type 1 DCs (cDC1), 
classical type 2 DCs (cDC2), and pDCs (23). The cDC1 sub-type 
is dependent on the transcription factor Baft3 and includes murine 
CD8+ DCs, murine CD103+ DCs, and human BDCA3+ DCs. The 
cDC2 sub-type requires the transcription factor IRF4 and includes 
murine CD4+ DCs and human BDCA1+ DCs, while the differentia-
tion of pDCs requires E2-2 transcription factor.
If in the murine DCs system, there is a degree of specialization 
of DC subsets for cross-presentation, with splenic CD8+ DCs and 
tissue resident CD103+ DCs being recognized as the most efficient 
cross-presenting subsets (16), in humans, all DC subsets display 
similar levels of ability for cross-presentation ex vivo (24). In addi-
tion to the DC populations found in homeostatic conditions, in 
inflammatory conditions, in both humans and mice, the monocytes 
can differentiate in several “DC-like” cellular populations known 
as monocyte-derived DCs. Considering their ontogeny, which is 
different from that of conventional DCs, the new name “monocyte-
derived cells” has been recently proposed for highly heterogeneous 
cellular populations that arise from monocytes in inflammatory 
conditions (23). Although sub-types of monocyte-derived cells 
are able to capture antigens in vivo and to cross present them via 
MHC I in vitro (25), their role in vivo for the priming of CD8+ T 
cells remains to be elucidated. The study of these subclasses will 
become possible as soon as the transcription factors required for 
their differentiation will be identified, to allow targeted depletion 
of specific monocyte-derived cells.
Some of DC subsets induce cross-tolerance in steady-state 
conditions (26–28) and cross-priming when the antigenic material 
contains a “danger signal” that will stimulate one of the pattern 
recognition receptors (PRRs) of DCs, such as toll-like-receptors 
(TLRs), NOD-like receptors (NLRs), or RIG-I-Like Receptors 
(RLRs) (29). Thus, phagocytosis of apoptotic cells, which lack 
“danger” signals and do not activate the PRRs, triggers an anti-
inflammatory response (30) and cross-tolerance. In contrast, 
phagocytosis of pathogens, which activates the PRRs, triggers an 
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inflammatory response and cross-priming. Signaling by PRRs 
thus leads to profound modifications of DCs, which become able 
to provide signals that are mandatory for cross-priming. These 
signals include recognition of peptide MHC complex (pMHC I) 
by the T cell receptor (TCR), followed by the interaction of DC’s 
co-stimulatory molecules CD80, CD86 with CD28 on T cells and 
polarized secretion of pro-inflammatory cytokines (IL-12) toward 
the immunological synapse (31).
In conclusion, a critical feature of DCs is their ability to coor-
dinate antigen presentation, including MHC I cross-presentation, 
with the physiological context, like the presence of inflammatory 
cytokines or danger signals from pathogens. Among the complex 
cell-intrinsic mechanisms that allow this coordination, the regula-
tion of MHC I trafficking during cross-presentation is a critical 
factor that will be discussed in detail in this review.
Accessory Cells involved in MHC i  
Cross-Presentation
In addition to DCs, several cell types were shown to be able to 
perform cross-presentation in particular situations. These include 
macrophages (32, 33), liver sinusoidal endothelial cells (LSECs) 
(34), endothelial cells (35), γδT cells (36), mast cells (37), and B cells 
(38). Although unusual, these events of cross-presentation might 
be relevant for CD8+ T cell priming against tumor antigens (33) 
or poorly vascularized transplanted organs (35). These particular 
antigen cross-presentation events are usually prompted by inflam-
matory conditions; with the exception of LSECs-mediated cross-
presentation that occurs under homeostatic conditions and leads 
to CD8+ T cell tolerance (39). Interestingly, even in the presence 
of inflammatory triggers, such as TLR4 ligands, the antigen cross-
presentation by LSECs remains tolerogenic (40), which indicates 
that cellular biology of antigen processing and cross-presentation 
in LSECs should be different from how it occurs in DCs.
Molecular Players involved in MHC i 
Assembly
MHC I is a heterodimeric complex containing a glycosylated 
transmembrane protein called heavy chain (HC), a small soluble 
protein, the beta-2 microglobulin (β2m) and a peptide ligand that 
is 8–10 aminoacids in length. In all nucleated cells of the body that 
can present endogenous antigens via MHC I, newly synthesized 
heavy chains (HC) are translocated in the endoplasmic reticulum 
(ER), where the HC assembly with β2m and peptide binding occurs. 
Like many other cells, DCs are also capable to present antigens that 
are expressed in their cytosol after endogenous protein synthesis 
from viral or endogenous mRNAs. During endogenous MHC I 
presentation, the antigenic peptides are produced in the cytosol 
by the concerted action of several cytosolic proteases, among 
which the proteasome contributes a major fraction (41). The ABC 
peptide transporter TAP transports these antigenic peptides from 
the cytosol in the ER, where they can bind the newly synthesized 
HC. MHC I assembly in the ER is a complex process in which a 
series of dedicated chaperons assist the correct folding of HC. 
An overview of molecular events leading to MHC I assembly 
and peptide loading in the ER, comprehensively reviewed in Ref. 
(42–44) is depicted in Figure 1.
After the binding of a high affinity peptide, MHC I complex 
may be exported outside ERGIC to reach the cell membrane. Both 
peptide-loaded and peptide free human MHC I can be visualized 
by immunoblot and fluorescence microscopy using conformational 
antibodies (e.g., W6.32 that recognizes peptide-loaded MHC I 
and HC-10 that detects free HC). It was thus possible to visualize 
peptide-free HC outside the ER, in the ERGIC, and cis-Golgi. Besides 
peptide-receptive MHC I (45), other components of MHC I peptide-
loading complex, such as functional TAP (46) and calreticulin or 
tapasin (47), have been detected in ERGIC, suggesting that peptide 
loading might occur outside ER, in the early secretory pathway. The 
molecular events involved in the exit of both pMHC and free HC 
of MHC I from the ER toward the Golgi stacks, remain unknown. 
The cytosolic tail of HC does not contain any previously described 
ER–Golgi trafficking signals (48), which suggests that MHC I may 
bind to cargo receptors, the identity of which remains elusive. Such 
a cargo was proposed to be Bap31, a transmembrane protein that 
cycles between ER and Golgi and interacts with both human and 
murine MHC I (49). However, knockdown of Bap31 does not lead 
to a decrease in MHC I expression at cell surface (50). Therefore, 
it has been suggested that additional and redundant mechanisms 
facilitate MHC I exit from the ER (51).
Pathways of Cell-Surface MHC i  
Recycling in Non-Professional  
Antigen-Presenting Cells
Depending on the cell type, between 50 and 180% of plasma 
membrane surface is constitutively recycled by endocytosis (52). 
Membrane internalization by clathrin-mediated endocytosis is 












FiguRe 1 | intracellular assembly of MHC i peptide complex. The newly 
synthetized heavy chain of MHC I interacts initially with Calnexin and 
associated thiol oxidoreductase ERp57, and is retained in the ER, where the 
HC associates with β2m. The HC–β2m complex interacts with the peptide-
loading complex (PLC) formed by Calreticulin, ERp57, Tapasin, and the peptide 
transporter TAP. Antigenic peptide precursors from cytosol are transported by 
TAP in the ER lumen, where they are processed by ER trimming 
aminopeptidases (ERAPs). Once the optimal epitope binds the HC–β2m 
complex, the MHC I is released from the PLC, is packaged into COP-II 
vesicles, and undergoes the anterograde transport on the secretory pathway. 
MHC I lacks obvious signal motifs for anterograde transport and the molecular 
events leading to MHC I packaging into COP-II vesicles remain unknown.
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on clathrin-mediated endocytosis, the adaptors involved and the 
sorting signals recognized by the clathrin adaptors, see Ref. (53)]. 
Less well characterized, but also very important are the routes 
of clathrin-independent endocytosis, such as caveolae-mediated 
uptake, macropinocytosis, and constitutive clathrin-independent 
uptake [reviewed in Ref. (54, 55)]. These internalization routes per-
mit endocytosis and recycling of plasma membrane proteins lacking 
any sorting signal for clathrin-mediated endocytosis, including the 
MHC I. Both fully conformed and empty MHC I are internalized 
via a clathrin- and dynamin-independent pathway. This pathway is 
ubiquitous, has been extensively studied in HeLa cells (56, 57), and 
requires free cholesterol and an active Arf6 GTP-binding protein.
The study of several mutant forms of Arf6 demonstrated that 
Arf6 is involved in both phosphoinositide kinase PI(4)P5K and 
phospholipase D activation (58–60). An Arf6-dependent formation 
of PIP2, the product of PI(4)P5K, might be required for the budding 
of tubular transport carriers directed to the plasma membrane (61), 
whereas the products of PLD activation could participate in a later 
fission step of such tubules in an analogous way to their proposed 
roles in the fission of COP-I transport carriers (62–64).
The majority of studies on Arf6-dependent endocytosis of MHC 
I analyzed the fully conformed MHC I recognized specifically by 
the conformational antibody W6.32. Recently, Zagorac et al. have 
investigated in parallel the endocytosis of fully conformed MHC I 
and empty MHC I (visualized by the non-conformational antibody 
HC-10), but without analyzing their colocalization with Arf6 (65). 
In this study, several alleles of fully conformed and empty MHC I 
were found in the same population of early endosomes. This sug-
gests either that both forms of MHC I are internalized by the same 
route, or that early after their internalization they converge toward 
the sorting endosomes (SE) independently of how the initial inter-
nalization step at the plasma membrane took place. Considering 
that empty MHC I and conformational MHC I seemed to localize 
to distinct membrane domains at the cell surface, and that empty 
MHC I is internalized five to eight times faster than conformational 
MHC I (66), it is possible that the initial internalization step is 
different for empty and fully conformed MHC I.
The dichotomy between empty and conformational class I 
trafficking is obvious in later steps of endocytosis. In these steps, 
empty MHC I colocalizes with EGF receptor in late endosomes 
and is directed to lysosomes. In contrast, fully conformed MHC 
I remains longer in the early endocytic pathway, its localization 
overlaps with early endosomal antigen 1 and transferrin receptor 
(65), and reaches endosomal tubular structures similar to the Eps 
15 homology domain protein 1 (EDH-1) recycling endosomes 
that require Arf6 activity (67). As a concluding remark of these 
studies, one might say that empty MHC I are rapidly internalized 
and at the level of SE are directed toward the lysosomes, while a 
part of conformational MHC I recycle back to plasma membrane 
by a tubular compartment, which requires Arf6, EDH-1 (67), and 
Rab22 and Rab11 (68, 69) [reviewed in Ref. (51)].
A Potential Role of ubiquitylation  
in MHC i endocytosis
Viral immune evasion mechanisms often depend on viral proteins 
that interfere with MHC I trafficking. Well-known examples are 
MHC I retention in the ER by the US3 protein of HCMV (70), 
cytosolic MHC I degradation by the US11 protein of HCMV (71), 
MHC I endocytosis promoted by the Nef-1 protein of human 
immunodeficiency virus (HIV) (72) or by the K3 and K5 proteins 
of Kaposi sarcoma-associated herpes virus (73). The last example 
suggests that a potentially important event in MHC I recycling 
could be the ubiquitylation of lysine 63 of its HC cytosolic tail by 
the K3 and K5 ubiquitin ligases. Ubiquitin provides a signal for 
protein incorporation into intralumenal vesicles of multivesicular 
bodies (MVBs), a subpopulation of late endosomes that fuse with 
lysosomes (74). Thus, ubiquitylated MHC I is directed to lysosomes 
where it is degraded (75), allowing virus-infected cells to escape 
recognition by cytotoxic T cells. Beside the involvement in immune 
evasion mechanisms, regulation of MHC I by ubiquitin ligases 
might be a physiological phenomenon, since an endogenous 
ubiquitin ligase family similar to K3 and K5 proteins was dis-
covered (76). This includes 11 mammalian membrane-associated 
RING-CH (MARCH) proteins that have been shown to increase 
the trafficking to late endosomes of several proteins internalized 
via clathrin-independent endocytosis (77). Among them, MARCH 
IV and MARCH IX over-expression leads to ubiquitylation and 
lysosomal degradation of MHC I (78), while MARCH I controls 
trafficking of MHC II during DCs maturation (79). The pattern of 
expression of MARCH IV and IX proteins in DC subpopulations, 
their transcriptional regulation, and their impact on both fully 
conformed and empty MHC I trafficking in DCs remain to be 
investigated and are of a great interest for the cellular biology of 
cross-presentation.
early Studies of MHC i Trafficking in DCs
Almost everything that we know about endocytosis and recy-
cling of MHC was learnt through the study of non-professional 
antigen-presenting cells, leading to the current overview of MHC I 
endocytosis depicted in Figure 2. However, a few studies on MHC I 
trafficking have been done in DCs, especially in monocytes-derived 
cells and DC-like cell lines. Early studies on murine DC-like cell 
line D1 (80) and human monocyte-derived DCs (81), showed that 
DCs activation by pathogens or TLR ligands increases MHC I 
biosynthesis and its stability at cell surface. Later studies discovered 
that MHC I intracellular distribution changes during DCs matura-
tion. Thus, Delamarre et al., when analyzing MHC I localization 
in murine bone marrow-derived DCs (BM-DCs), demonstrated 
that in immature BM-DCs MHC I is intracellular, colocalizing 
with the Golgi marker GM130. Upon BM-DCs maturation by LPS 
and cluster disruption, the expression of MHC I at cell surface is 
up-regulated, being sevenfold higher than in immature BM-DCs 
(82). Like in BM-DCs, in human monocyte-derived DCs and in 
a DC-like cell line (KG-1), MHC I trafficking is regulated during 
DCs maturation (83). In immature human DCs, cell-surface MHC 
I has a short half-life at cell surface and about 60% of MHC I is 
sequestered in the proximal Golgi apparatus, colocalizing with 
GM130, γ-adaptin, and GRASP22. Upon DC activation by LPS, 
MHC I is relocated at cell surface, where it has an increased half-
life, in correlation with down regulation of its endocytosis (83). 
The molecular adaptors that retain MHC I in Golgi remain still 












FiguRe 2 | Pathways of MHC i recycling. Mammalian cells have two 
major pathways of endocytosis, clathrin-dependent endocytosis (CDE) and 
clathrin-independent endocytosis (CIE). MHC I molecules are internalized via 
CIE and arrive in sorting endosomes (SE). Depending on their conformation 
and their ubiquitination status, the MHC I are either recycled or directed to 
multivesicular bodies (MVB). The recycling of MHC I occurs via the endocytic 
recycling compartment (ERC) described by the small GTPase Rab11 or via 
tubular structures dependent on Rab22 and Arf6 (68, 69). Among these 
MHC I recycling pathways that were described in HeLa cells, only the MHC I 
from Rab11+ ERC was recently explored for their function in cross-
presentation after antigen phagocytosis (118).
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has been reported to be required for MHC I anterograde transport 
from the ER in B cells (84). Different from monocyte-derived DCs, 
in immature human Langerhans cells (LCs), MHC I is stored 
in intracellular vesicles, partially overlapping with HLA-DM. 
LPS-induced maturation of LCs only modestly increases MHC I 
biosynthesis, but induces a rapid mobilization of the intracellular 
pool of MHC I to cell surface (85).
These initial studies on MHC I localization in human 
monocyte-derived DCs and LC indicate that the intracellular 
localization and trafficking regulation vary from one DC type 
to another. A careful and systematic examination of MHC I 
localization in several DC subpopulations has not been done 
yet. Nevertheless, this will be required in the future, to be 
able to estimate to what extent the molecular mechanisms 
regulating MHC I trafficking in monocyte-derived DCs, which 
will be discussed in subsequent sections of this review, operate 
in other DC subsets.
Pathways of Antigen Processing During 
Cross-Presentation
Early studies on molecular mechanisms allowing exogenous 
antigens presentation on MHC I established that two major path-
ways of antigen processing exist during cross-presentation: one 
that is TAP and proteasome-dependent and another that is TAP 
and proteasome-independent. In the proteasome-independent 
cross-presentation, known as vacuolar cross-presentation, 
acidic lysosomal proteases, among which the Catepsin S seems 
to have a major role (86), generate the MHC I ligands in the 
endocytic pathway. Therefore, in proteasome-independent cross-
presentation, MHC I loading occurs in endocytic vesicles. The 
vacuolar route of MHC I cross-presentation is considered to 
be less effective than proteasome-dependent cross-presentation 
(87). Nevertheless, from the data available today it is problematic 
to get definitive conclusions on the relative importance of each 
cross-presentation pathway because proteasome inhibition has 
pleiotropic cellular effects while TAP deficiency also alters MHC 
I trafficking.
Contrary to vacuolar cross-presentation in which the antigen 
processing occurs in the endocytic vesicles, TAP and proteasome-
dependent cross-presentation involves transport of exogenous anti-
gen from the endocytic pathway to the cytosol. The unique ability 
of DCs to export the antigenic material from the endocytic vesicles 
to the cytosol (88) is probably the key feature that allows them 
to excel in cross-presentation of exogenous antigens. Antigenic 
material shuttled into cytosol is digested by the proteasome, which 
is the main cytosolic broad substrate specificity protease. The 
proteasome generates precursors of antigenic peptides that are 
longer than 8–10 amino acids, which is the optimal peptide length 
for an MHC I ligand (89). Thus, the ligand precursors generated by 
the proteasome have rarely the optimal length and require further 
processing by accessory peptidases, either in the cytosol or in the 
ER [for a review, see Ref. (90)].
Aminoterminal Trimming of Antigen 
Precursors and MHC i Loading 
Compartments During Cross-Presentation
The enzymes that perform the final step of antigen processing for 
MHC I antigen presentation belong to the same subfamily (IRAP 
subfamily) of M1 metallo-peptidases and are encoded by genes 
located in the same region of human chromosome 5. In humans, 
this family includes two ER localized enzymes, ER trimming 
aminopeptidases (ERAP)1 and ERAP2 (91), and the endosomal 
enzyme insulin-responsive aminopeptidase (IRAP) (92). Rodents 
have only two antigen trimming aminopeptidases, IRAP in 
endosomes, and the equivalent of human ERAP1, ERAAP in the 
ER (93). ERAPs are soluble, intraluminal proteins, while IRAP 
is a type II transmembrane protein that bears an intracytosolic 
domain of 110 amino acids. This cytosolic domain contains all 
the information required for IRAP trafficking, as demonstrated 
by extensive study of the enzyme in insulin-responsive tissues 
(94, 95), where a major cargo of IRAP vesicles is the insulin-
regulated glucose transporter Glut4 (96). In DCs, IRAP is found 
in intracellular vesicles that contain also MHC I molecules, the 
small GTPase Rab14, and the Q-SNARE Syntaxin 6. These vesicles 
are recruited to early phagosomes and endosomes containing the 
internalized antigen and facilitate cross-presentation ability of 
DCs by antigen trimming function of IRAP (92, 97). Interestingly, 
IRAP not only colocalizes with internalized MHC I molecules, 
but also co-immunoprecipitates with MHC I. Why the endosomal 
trimming aminopeptidase interacts with MHC I is still unknown. 
The close proximity of IRAP and MHC I molecules might facilitate 
the loading of MHC I in endosomes and phagosomes, an environ-
ment that might be less favorable than the ER for class I loading. 
Alternatively, IRAP, which bears two di-leucine motifs in its 
cytosolic domain might interact with clathrin adaptors and direct 
the vesicular trafficking of MHC I molecules. To understand the 





















FiguRe 3 | MHC i loading compartments during cross-presentation. 
(1) The antigen precursors produced in the cytosol of DCs can join the 
classical MHC I presentation pathway and can be transported by TAP in ER. 
In ER, the final trimming of antigen precursors is performed by the ER 
aminopeptidases (91, 93, 121, 122) and the resulting peptides bind to newly 
synthetized empty MHC I (92, 123, 124). (2 and 3) Proteasome digestion 
products generated in the cytosol of DCs can be retro-transported in 
phagosomes (111, 112, 114) or specialized endosomes (117, 125). The final 
step of antigen processing is probably done by IRAP which is the main 
trimming aminopeptidase recruited to the phagosome and colocalizing with 
mannose receptor endosomes (92). (4) Alternatively, in proteasome-
independent cross-presentation (vacuolar pathway of cross-presentation), 
the exogenous antigen is entirely processed in the endocytic pathway by 
endolysosomal hydrolases (86).
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The discovery and detailed characterization of the localization of 
trimming peptidases and their roles in cross-presentation allowed 
us to speculate on the cellular compartments in which MHC I is 
loaded with peptides (Figure 3). In the proteasome-dependent 
cross-presentation pathways, these compartments are the perinu-
clear ER, the phagosomes, and the specialized endosomes, while 
in the vacuolar pathway of cross-presentation the MHC I loading 
occurs in late endosomes or lysosomes.
The intracellular Origin of  
Cross-Presenting MHC i
Although, theoretically, MHC I loading with exogenous peptides 
during cross-presentation could take place in the perinuclear ER, 
several lines of evidence accumulated in the last decades that in, 
DCs, the main components of antigen processing machinery have 
access to antigen containing endosomes and phagosomes. This 
enhanced access is likely to contribute to a high efficiency of the 
cross-presentation phenomenon, as summarized in the Figure 3. 
The existence of peptide-receptive MHC I molecules is the pri-
mordial ingredient for cross-presentation. Thus, to understand 
the molecular mechanisms of cross-presentation, the origin of 
MHC I molecules that are loaded with exogenous peptides in the 
endocytic pathway is a central question investigated by several 
recent reports.
In the proteasome-independent vacuolar pathway of cross-
presentation, initial studies clearly indicated that the MHC I that 
are loaded with antigenic peptides are recycling MHC I (98–101), 
even if the molecular mechanisms of MHC I endocytosis and 
recycling have not been investigated systematically in that work. 
However, the most recent exploration of MHC I intracellular 
localization during cross-presentation gave new insights into 
MHC I vesicular trafficking. Thus, in a model of viral infections 
as well as soluble ovalbumin cross-presentation, Lizée et  al. 
demonstrated that a conserved tyrosine in the cytosolic tail of 
MHC I is required for MHC I endocytosis and its targeting to 
lysosomal vesicles (102). The lysosomal-targeted class I molecules 
were probably loaded with antigenic peptides generated in the 
endocytic pathway, although the proteasome dependence of the 
cross-presentation models used in these studies (102, 103) has 
not been investigated. The molecular mechanism by which the 
tyrosine residue in the cytosolic tail of MHC I favors its endocy-
tosis and lysosomal targeting remains enigmatic and the cytosolic 
adaptor that recognizes this MHC I trafficking motif remains to 
be identified.
Additional evidence that the cytosolic tail of MHC I contains 
a cryptic sorting signal around the previously mentioned tyrosine 
residue comes from the study of molecular mechanisms by which 
the HIV down-regulates the cell-surface MHC I level (104–106). In 
the presence of HIV Nef protein, the cryptic signal YXXXAXXD of 
MHC I binds the AP-1 clathrin adaptor (107) and this trimolecular 
complex directs MHC I to endosomes and lysosomes. Interestingly, 
while in the presence of Nef protein, the cross-presentation by 
MHC I containing the tyrosine signal (HLA-A2, HLA-B) is com-
promised, both the clathrin adaptor AP-1 and the tyrosine motif 
of MHC I are absolutely required for cross-presentation of soluble 
ovalbumin (108). If these data clearly indicate a role for AP-1 in 
targeting MHC I from trans Golgi to intracellular vesicles prior 
to presentation at the cell surface, the nature of these intracellular 
vesicles nor the mechanism of AP-1 binding to MHC I in the 
absence of Nef is known. The example of HIV Nef protein that 
reorients MHC I trafficking at trans Golgi level via AP-1 clathrin 
adaptor might indicate the existence of an endogenous protein 
that can substitute for Nef protein and ensure AP-1 binding to 
MHC I. Such a candidate is the class II invariant chain Ii, which 
binds AP-1 clathrin adaptor (109) and which has been shown to 
be required for MHC I sorting to endosomes and lysosomes (110).
The majority of data supporting the role of MHC I cytosolic 
tail in MHC I trafficking and cross-presentation were obtained in 
cross-presentation settings that often used soluble antigens and 
were possibly proteasome-independent. To what extent these 
findings apply to phagosome-mediated and receptor-targeted 
cross-presentation, which are usually proteasome-dependent, 
remains to be elucidated.
Contrary to vacuolar cross-presentation, in the proteasome-
dependent cross-presentation, the source of MHC I molecules 
that are loaded with exogenous peptides has been considered for 
a long time to be the MHC I from the ER. This assumption is also 
compatible with the fusion of ER with phagosomal membranes, 
which provide to phagosomes several components of MHC I 
antigenic presenting machinery, including MHC I molecules 
(111–113). It is likely that ER-phagosome fusion results in a 
mixed population of MHC I molecules, since both Endo H sensi-
tive (ER form) and Endo H resistant (surface form) MHC I can 
be detected in phagosomes [(114) and our unpublished results]. 
Several recent data allow us to reconsider this original hypothesis 
and seem to indicate that the source of MHC I involved in protea-
some dependent cross-presentation is not the newly synthetized 
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class I from the ER. Thus, we have showed that preincubation of 
TAP-deficient DCs at 26°C increases the cell-surface level of MHC 
I and fully restores the cross-presentation of phagocytized antigens, 
in a model of proteasome-dependent cross-presentation (115). 
These experiments suggest that MHC I molecules from the late 
steps of secretory pathways or from the cell surface are essential 
in proteasome-dependent cross-presentation of phagosomal anti-
gens. Interestingly, in the same study, the recovery of cell-surface 
MHC I by low temperature incubation of TAP-deficient DCs did 
not restore the cross-presentation of antigen targeted ovalbumin, 
indicating either that the source of loadable MHC I are different 
between phagocytized and receptor-targeted antigens, or that 
the phagosomes, but not the endosomes, are equipped with an 
alternative mechanism for peptide import, such as Sec61 (114).
Further proof in favor of the involvement of the recycling 
MHC I in proteasome-dependent cross-presentation was provided 
by a recent study performed in the DC-like cell line DC2.4, in 
which the cross-presentation of E. Coli expressing ovalbumin was 
investigated after siRNA-mediated inactivation of 57 Rab proteins 
(116). Several Rabs were required for optimal cross-presentation, 
such as Rab3b, 3c, 5b, 8b, 10, 33a, 34, and 35. Among them, Rab3 
seems to be required for recycling of cell-surface MHC I, as 
demonstrated using ZsGreen β2m as a tracker. Additional strong 
evidence against the implication of ER localized MHC I molecules 
in cross-presentation of phagosomal antigens result from a very 
recent study on Rab11 role in MHC I trafficking during cross-
presentation that will be presented in the next paragraphs.
Control of MHC i Antigen Cross-
Presentation by TLR Signaling
The well-known ability of cross-presentation to induce both T 
cell priming and T cell tolerance is associated to activation of 
PRRs (29), among which the most potent and the best studied 
are the TLRs. The increase in co-stimulatory molecules and pro-
inflammatory cytokine production by DCs enhance the potential 
of TLR-activated DCs to cross-prime the naïve CD8+ T cells. In 
addition to these effects of TLR activation, it has been recently 
demonstrated that the intracellular trafficking of two essential 
components of MHC I antigen-presentation machinery, TAP, 
and MHC I is regulated by TLR signaling (Figure 4). In a model 
of mannose receptor (MR) targeted cross-presentation, Burgdorf 
et al. demonstrated that TAP is enriched in MR endosomes upon 
DCs stimulation by a TLR4 ligand, the LPS (117). In a model 
of cross-presentation upon phagocytosis of yeast cells expressing 
ovalbumin, we detected a moderate increase in the amount of TAP 
recruited on phagosomes containing yeast cells when compared 
with the phagosomes containing latex beads (92). More recently, 
it has been shown that Sec22b-mediated fusion of ERGIC derived 
vesicles to the phagosome even in the absence of TLR ligands on 
the phagosomal cargo (113), suggesting that the recruitment of 
TAP to phagosomal membrane is less dependent on TLR stimula-
tion than the recruitment of MHC I.
The supply of MHC I molecules to the phagosomes is strongly 
enhanced by TLR stimulation (118). Nair-Gupta and colleagues 


















FiguRe 4 | TLRs activation facilitates the recruitment of MHC i and 
TAP to antigen containing vesicles. (1) Following TLR activation, the 
downstream signaling cascade involving MyD88 drives phosphorylation of 
SNAP23 by IkB-Kinase (IKK2). Phosphorylated SNAP23 facilitates MHC I 
recruitment from Rab11+ ERC to phagosomal membrane, probably by 
stabilization of SNARE complexes (118). (2) Sec22b-mediated ER–
phagosome fusion provides TAP to the phagosomal membrane in the 
absence of TLR activation (113). A further increase in TAP recruitment to 
antigen containing vesicles, such as MR+ endosomes (117) and yeast 
containing phagosomes (92), has been observed after TLR stimulation. The 
underlying molecular mechanisms remain to be investigated.
signaling cascade induces the IKK2-dependent phosphorylation 
of synaptosome-associated protein of 23 kDa (SNAP 23) on the 
phagosomes containing the TLR ligand. The phosphorylated 
SNAP23/Syntaxin 4 (STX4) complex recruits the t-SNARE 
VAMP3 and this molecular complex mediates the membrane 
fusion between endosomes containing MHC I and phagosomes. 
The VAMP3 endosomal compartment that contains MHC I is 
described by the small GTPase Rab11a and is identified as the 
endosomal recycling compartment (ERC). How MHC I molecules 
are stored in DCs in the VAMP3+ Rab11+ ERC and if they are 
directly targeted from the transGolgi network to ERC or if they 
are internalized from the cell membrane is still unknown. The 
importance of tyrosine in the cryptic sorting motif of the cytosolic 
tail of MHC I and the role of AP-1 clathrin adaptor in MHC I 
targeting to VAMP3+ Rab11a+ ERC remain to be investigated as 
well. Finally, since SNAP 23 has the ability to interact not only with 
STX4 and VAMP3, but also with several others SNAREs (STX2, 6, 
11, VAMP2, 8), the activation of SNAP 23 by TLR signaling might 
trigger important changes in vesicular trafficking in DCs. Thus, 
this regulation of membrane fusion machinery by TLR signaling 
might be an important checkpoint for antigen presentation and 
immunogenic capacities of DCs.
Concluding Remarks
Cross-presentation of exogenous antigens via MHC I is a complex 
phenomenon, which is largely based on the high plasticity of 
the endocytic system in DCs. The main ingredient for successful 
cross-presentation is the presence of peptide loadable MHC I in 
the cellular compartment where the antigenic peptide is pro-
duced. While the pathways of intracellular trafficking of MHC 
I have been fairly well studied in model cell lines, such as HeLa 
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cells, the study of MHC I trafficking in DCs is still in a pioneer 
stage and the few cellular biology studies focused on mouse 
BM-DCs. However, we think that the time has come to develop 
this topic since it could fully benefit from the comprehensive char-
acterization of DC subpopulations and their equivalence between 
humans and rodents (23). In combination with the availability of 
high-resolution microscopy and excellent conformation-specific 
antibodies against human MHC I (119, 120), the characteriza-
tion of MHC I trafficking in human DC subpopulations became 
possible.
Considering the well-known ability of signaling through PRRs 
to increase the immunogenic abilities of DCs, including cross-
presentation (29) it is of outstanding interest to determine how 
TLR signaling regulates MHC I trafficking in DC subpopulations. 
The recent work of Nair-Gupta et al. has provided some insights 
on MHC I recruitment from Rab11+ ERC to antigen-containing 
phagosomes in mouse BM-DCs upon TLR2 and TLR4 activation 
via the MyD88 signaling pathway (118). To what degree these 
interesting findings apply to steady-state DC subpopulations or to 
accessory cross-presenting cells? Are Rab11+ ERCs a TLR-regulated 
reservoir of MHC I in all cells capable of cross-presentation? Is 
the TRIF-dependent signaling pathway able to regulate MHC I 
trafficking? Answering these questions in the near future would 
pave the way to a mechanistic comprehension of MHC I cross-
presentation regulation through modulation of intracellular MHC 
I trafficking.
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